Skip to main content
Fig. 1 | Journal of Innovation and Entrepreneurship

Fig. 1

From: A novel valuation model for medical intervention development based on progressive dynamic changes that integrates Health Technology Assessment outcomes with early-stage innovation and indication-specific clinical success rates

Fig. 1

Stage-specific rNPV calculations for the four modelled interventions, using generic success rates comparing abbreviated or full high and low costs, and indication-specific success rates comparing abbreviated or full high and low costs. rNPV calculations were made for chemical entity or biological interventions for diabetic or heart disorders using low and high versions of abbreviated or full economic costs and generic success rates (panels a, b, c, and d) and for the latest indication-specific success rates (panels e, f, g, and h)

Back to article page